Vitiligo is a chronic autoimmune condition characterized by the loss of pigment-producing cells (melanocytes), resulting in white patches on the skin and sometimes hair or mucous membranes.
Ranked by community outcomes, then evidence grade, Health Voice mentions, and recency.
Why it may help Vitiligo: Often low and supports repigmentation
Why it may help Vitiligo: Antioxidant support for skin
Why it may help Vitiligo: Supports melanocyte function
Why it may help Vitiligo: Folate (5-MTHF) may support repigmentation in vitiligo by aiding in the synthesis of tetrahydrobiopterin, a cofactor essential for melanin production, and by reducing oxidative stress that contributes to melanocyte damage.
Why it may help Vitiligo: B12 and folate may aid repigmentation
Why it may help Vitiligo: Anti-inflammatory for autoimmune skin
Why it may help Vitiligo: Topical and oral support
Why it may help Vitiligo: Antioxidant for melanocyte preservation
Why it may help Vitiligo: N-Acetyl Cysteine may help vitiligo by increasing glutathione levels, thereby reducing oxidative stress that damages melanocytes and contributes to the progression of depigmentation.
A potent antioxidant studied for diabetic neuropathy and insulin sensitivity.
Circulatory herb for cognition, memory, and microvascular flow.
Community outcomes
Self-reported by community members · not medical advice.
Self-reported community outcomes. Not medical advice. Requires at least three reports per remedy to surface.
Community outcome data is still being collected for this ailment.
Be the first to share your experience →As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.
Structured experience reports from people managing this condition. Not medical advice.
You can share without an account — we'll send a one-time code to verify your email. Or sign in.
Loading posts…
Community Discussions
How global health authorities view Vitiligo.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the NIH, acknowledges that while conventional treatments exist, research into the underlying causes and potential new therapies, including those involving nutritional and herbal compounds, is ongoing. They emphasize the importance of sun protection for affected areas. The Mayo Clinic also highlights the role of sun protection and stress management. While specific natural remedies are not universally endorsed by these bodies as primary treatments, the importance of a healthy lifestyle and addressing nutritional deficiencies is often recognized as supportive care.
Indexed studies for Vitiligo, grouped by source type and quality.
Filter by source type
Pooled analyses across multiple human trials.
Systematic evidence grading evaluates multisystemic associations and risks of vitiligo.
Liu L, Xue Y, Liu W, Cui J, Lv H, Chang J · Nature communications · 2025
Vitiligo, a chronic autoimmune skin disorder characterized by refractory depigmentation, has inconsistent associations with various biomarkers and diseases due to confounding factors. Here, we conduct a comprehensive umbrella review and comparative analysis to evaluate the validity and strength of evidence from observational studies on vitiligo. 103 meta-analyses and 150 Mendelian randomization (MR) analyses are included, spanning categories including cardiometabolism, cancer, autoimmune, dermatosis, psychiatry/neurology/senses, and biomarkers/lifestyle. Evidence grading reveals seven convincing meta-analysis findings: five factors (fasting blood glucose, Graves' disease, thyroid antibodies, cataracts, and glaucoma) are associated with an increased risk of vitiligo, while vitiligo is related to two conditions (a decreased risk of overall cancer and an increased risk of inflammatory bowel disease). Future similar research is unlikely to alter these findings according to fail-safe number
Mohammed AA, Lengyel AS, Meznerics FA, Szondy I, Walter A, Szabó B · Dermatology and therapy · 2025
Vitiligo, a chronic skin disease affecting 1-2% of the global population, is associated with significant impairment in quality of life. Current pharmacological treatment options have limited efficacy and considerable side effects. Recent studies have shown promising results when using Janus kinase inhibitors (JAKis). Despite these favourable findings, there remains a critical need for comprehensive data on the efficacy and safety of JAKi in the treatment of vitiligo. Three databases were searched for studies on patients with vitiligo treated with oral or topical JAKi, with or without conventional therapy. Placebo or vehicle cream were comparators in randomised controlled trials (RCTs). Outcomes included a 75% improvement in Facial-Vitiligo Area Scoring Index (F-VASI), mean Vitiligo Area Scoring Index (VASI) improvement, repigmentation percentage and adverse events. We performed three analyses: one using RCT data, one from case reports and a novel cohort of JAKi-treated patients from c
Risk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence.
Liang X, Guo F, Zhang M, Wang C, Lin N, Liu L · Annals of medicine · 2024
The relationship between vitiligo and cardiovascular diseases remains controversial. This study aimed to systematically review the evidence comparing cardiovascular disease risk factors between patients with vitiligo and controls and to perform a meta-analysis of the results. A comprehensive database search was performed for all studies in PubMed, EMBASE, and Cochrane Central Register databases from inception to November, 2023. The main keywords used were vitiligo, hypertension, diabetes, hyperlipidemia, metabolic syndrome, obesity, smoking, alcohol consumption, C-reactive protein, and homocysteine. Only observational studies and no randomized controlled trials were included. Of the 1269 studies initially selected, the full texts of 108 were assessed for eligibility, and 74 were ultimately included in the analysis. Three reviewers independently extracted the following data: study design, number and characteristics of participants, inclusion indicators, and disease duration. A meta-a
Structured reviews of the full body of evidence (incl. Cochrane).
Radi TO, Larche CL, Pereira A, Tang T, Derzko-Dzulynsky L, Bakshi N · Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2026 · n=16
To synthesize and critically appraise the available evidence on choroidal vitiligo, integrating clinical presentation, multimodal imaging characteristics, and diagnostic differentiation from mimics, while proposing a set of diagnostic criteria based on literature synthesis and authors' expert consensus. A systematic search of PubMed, Embase, and Cochrane Reviews through July 2025 identified English-language studies reporting on choroidal vitiligo. Two reviewers independently screened, extracted data, and assessed methodological quality for case reports and case series. Narrative synthesis and descriptive statistics were used to summarize the findings. Eight studies met inclusion criteria, comprising 16 patients (28 eyes) from 5 countries. The majority of patients (75%) were asymptomatic, middle-aged females, with bilateral involvement in 88% of cases and preserved visual acuity (≥20/25 in 81% of eyes). Multimodal imaging consistently revealed well-demarcated choroidal hypopigm
Vitiligo and the microbiome of the gut and skin: a systematic review.
Nigro A, Osman A, Suryadevara P, Cices A · Archives of dermatological research · 2025
Vitiligo is a chronic autoimmune skin condition characterized by depigmentation due to the destruction of melanocytes. Recent research has identified potential links between vitiligo and alterations in both the gut and skin microbiomes. This systematic review aims to explore these microbiome changes and their potential role in the onset and progression of vitiligo. A comprehensive search of the PubMed, Medline (OVID), and Web of Science databases was conducted to identify studies examining the gut and/or skin microbiota in vitiligo patients. A total of six studies were included in the qualitative analysis. Data extracted included study type, patient demographics, microbiome sampling methods, bacterial diversity, and bacterial ratios. The studies were assessed using the Methodological Index for Non-Randomized Studies (MINORS) scale. The results revealed inconsistent findings regarding microbial diversity in vitiligo patients. Some studies observed decreased α-diversity in the gut
Estimating the burden of vitiligo: a systematic review and modelling study.
Akl J, Lee S, Ju HJ, Parisi R, Kim JY, Jeon JJ · The Lancet. Public health · 2024
Vitiligo is a chronic autoimmune disease characterised by depigmented skin patches, which can pose substantial psychosocial challenges particularly in individuals with dark skin tones. Despite its impact on quality of life, there is an absence of standardised global epidemiological data. We sought to address this gap with the present study. In this study we did a systematic review and modelling analysis to estimate the global, regional, and national prevalence and incidence of vitiligo. We did a comprehensive search of nine digital libraries (PubMed, Embase, Web of Science, Scientific Electronic Library Online, KCI Korean Journal Database, Russian Science Citation Index, Western Pacific Region Index Medicus, Informit, and Health Research and Development Information Network) from inception up to May 25, 2023. We included cross-sectional or cohort studies reporting the incidence rate or prevalence of vitiligo, or data from which incidence rate or prevalence could be calculated, in the g
Controlled human studies with random assignment.
Wang Y, Lin M, Huang F, Jia R, Xu W, He Q · Journal of cosmetic dermatology · 2024 · n=29
Vitiligo remains a challenging condition to treat. Fire needle therapy, a traditional Chinese medicine technique, has potential as an alternative therapeutic strategy. However, rigorous evidence on its efficacy is lacking. We aimed to evaluate the efficacy and safety of fire needle therapy, alone and combined with topical tacrolimus ointment, for non-segmental stable vitiligo. In this 6-month randomized self-controlled trial, 35 vitiligo patients were enrolled, providing three similar lesions each. Lesions were randomly allocated to receive fire needle monotherapy, 0.1% tacrolimus ointment monotherapy, or combined fire needle and tacrolimus ointment therapy. The main outcome was change in vitiligo surface area. In total, 29 patients completed the 6-month follow-up. The combination therapy group showed significantly greater reductions in vitiligo surface area compared to monotherapy groups starting at months 4 and 5. By the end of the study, combination therapy resulted in remarkably
Cohort, case-control, and cross-sectional human studies.
Rathod DG, Muneer H, Masood S · 2026
Recent Advances in Vitiligo Treatment.
Qiu Y, Su X, Chen J, Jiang S, Tang X, He Y · ImmunoTargets and therapy · 2026
This review systematically summarizes breakthrough advances in vitiligo treatment from 2020 to 2025 to provide the latest evidence-based insights for clinical practice. We searched ClinicalTrials.gov and PubMed for literature and clinical trials published within this period. Inclusion criteria encompassed randomized controlled trials (RCTs), Phase II and above clinical trial results, and fundamental research with clear clinical translational value. Our analysis identified that JAK inhibitors achieved significant repigmentation by blocking the IFN-γ/JAK-STAT signaling pathway, while novel agents such as IL-15 inhibitors selectively eliminated pathogenic CD8⁺ T cells, suppressing immune-mediated damage at its source. The combination of 308 nm excimer laser with JAK inhibitors or platelet-rich plasma (PRP) increased repigmentation rates in acral lesions to 56.1%, and vitamin D adjunct therapy demonstrated synergistic effects. For stable disease, ReCell technology combined w
Yan C, Jiang L, Hu Y, You T, Chen J, Wu S · Dermatology and therapy · 2025
Given that the proteome is a major source of therapeutic targets, we conducted a proteome-wide Mendelian randomization (MR) combined with transcriptome sequencing analysis to identify candidate protein markers and therapeutic targets for vitiligo. Based on protein quantitative trait loci (pQTLs) and genetic associations with vitiligo obtained from the European Bioinformatics Institute (EBI) database (60 vitiligo cases and 402,672 controls), and the UK Biobank (95 vitiligo cases and 337,064 controls), bidirectional MR and colocalization analyses identified genetically predicted levels of nine proteins collectively linked to vitiligo risk. Based on the RNA-seq data and single-cell RNA-seq data of vitiligo, bioinformatics analysis and model prediction of genes associated with vitiligo progression evaluated the relationship between candidate core proteins and the development of vitiligo. Four proteins (KLF4, MYL4, TNFRSF13C, TNFSF13B) were associated with lower vitiligo risk, while five
Preclinical animal research — not a substitute for human evidence.
Ni Q, Xia L, Huang Y, Yuan X, Gu W, Chen Y · Microbiome · 2025
Vitiligo, a depigmenting autoimmune skin disease characterized by melanocyte dysfunction or death, is known to be associated with an imbalance in gut microbiota. Oxidative stress plays a critical role in the pathogenesis of vitiligo. However, the complex promising interaction between abnormal accumulation of reactive oxygen species (ROS) in the skin and gut microbiota has remained unclear. Here, we compared transcriptome data of vitiligo lesions and normal skin and identified a high expression of oxidative stress-related genes in vitiligo lesions. We also established a vitiligo mouse model and found that the presence of gut microbiota influenced the expression of ROS-related genes. Depletion of gut microbiota reduced abnormal ROS accumulation and mitochondrial abnormalities in melanocytes, significantly improving depigmentation. Our findings from manipulating gut microbiota through cohousing, fecal microbiota transplantation (FMT), and probiotic supplementation showed that transferrin
Public-health agencies: NCCIH, NIH, CDC, NHS.
NHS
This section of the NHS website focuses specifically on the various treatment approaches available for managing vitiligo.
Registered ongoing or completed trials (ClinicalTrials.gov).
Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients
n=200 · NCT00525395 · UNKNOWN · UNKNOWN
Background Phototherapy UVB TL01 currently represents the first choice in treatment to induce the repigmentation of vitiligo spots. The problem though is that there are no systems or scales which enable an objective evaluation of the therapy, commonly known as percentage of repigmentation. Recently, a European Task Force (VETF, Vitiligo European Task Force) of experts on vitiligo, within the European Society of Pigmentation, has proposed a gravity classification on the basis of three parameters/standards - extension, progression and the level of depigmentation - and used to classify patients in ten European centres. The aim of the trial is to validate the VETF scoring system set up in relation with the therapeutic answer to the standard treatment for vitiligo and phototherapy. Leaving aside short term side effects, such as sunrush/erythema and sunburn, which are reversible and infrequent, the main problem with phototherapy is represented by the cumulative long term effects of ultraviolet rays. These can cause premature ageing of the skin (photoaging) and the appearance of skin cancer/neoplasia. Therefore the aim is to get the best results from phototherapy whilst limiting its length. Aims of the trial: 1. To validate the VETF scoring system. As phototherapy is currently the only universally accepted treatment for vitiligo, it seems logical to test the VETF scoring system first to evaluate the effectiveness of phototherapy. 2. Secondly, the target of this multicentric trial is to compare the effectiveness of two different phototherapy protocols; a first protocol foresees non-stop treatment for 6 months; a second protocol foresees periods of interruption during the treatment. This will help to verify whether interrupting a cycle of phototherapy is useful or not. This interruption might make the ultraviolet rays more effective 'stimulus on the melanocytes', and may also reduce long term damage caused by phototherapy.
Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial
n=16 · NCT01787708 · UNKNOWN · UNKNOWN
Vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin. There are many treatment modalities available for vitiligo, however, none of them cure the disease. Visible red light has been shown to stimulates melanocyte migration and proliferation resulting in repigmentation of vitiligo patches. However, there are only a few studies published on the efficacy of red light in vitiligo. This is a prospective single-blind randomized clinical trial to assess efficacy of red light in the treatment of vitiligo.
n=56 · NCT01430195 · COMPLETED · COMPLETED
The purpose of this study is to look at the efficacy of afamelanotide, when combined with narrow-band ultraviolet B (NB-UVB) light, in patients with nonsegmental vitiligo. Afamelanotide is expected to speed up the repigmentation induced by NB-UVB light, leading to reducing frequency and doses of NB-UVB.
Curated cross-source summaries (TRIP Database and similar).
TRIP Database
The TRIP Database is a clinical search engine designed to allow users to quickly find high-quality research evidence. A search for 'vitiligo' can yield relevant clinical guidelines, systematic reviews, and other evidence-based resources.
Cochrane
Cochrane provides access to systematic reviews of interventions for vitiligo, offering high-quality evidence to inform clinical decisions.
Conventional medical treatments for vitiligo include topical corticosteroids, calcineurin inhibitors, phototherapy (UVB), excimer laser, and surgical options like skin grafting for stable patches. These treatments aim to repigment the skin or slow the progression of depigmentation. A dermatologist can provide a comprehensive diagnosis and discuss the most appropriate treatment plan based on the in
Latest News
Health Videos
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making any decisions about your health or treatment, especially if you have vitiligo or any other medical condition.
Found something that helped your vitiligo?
Help others see what actually works.
Found something that helped your vitiligo?
Real-world results help others choose what's worth trying.